- Home
- GRFS vs AXSM Comparison
GRFS vs AXSM Comparison
Compare GRFS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- AXSM
- Stock Information
- Founded
- GRFS 1940
- AXSM 2012
- Country
- GRFS Spain
- AXSM United States
- Employees
- GRFS N/A
- AXSM N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GRFS Health Care
- AXSM Health Care
- Exchange
- GRFS Nasdaq
- AXSM Nasdaq
- Market Cap
- GRFS 5.9B
- AXSM 5.9B
- IPO Year
- GRFS 2006
- AXSM 2015
- Fundamental
- Price
- GRFS $8.39
- AXSM $152.72
- Analyst Decision
- GRFS Hold
- AXSM Strong Buy
- Analyst Count
- GRFS 1
- AXSM 20
- Target Price
- GRFS $10.30
- AXSM $176.00
- AVG Volume (30 Days)
- GRFS 779.1K
- AXSM 591.4K
- Earning Date
- GRFS 01-01-0001
- AXSM 11-03-2025
- Dividend Yield
- GRFS 1.70%
- AXSM N/A
- EPS Growth
- GRFS N/A
- AXSM N/A
- EPS
- GRFS 0.64
- AXSM N/A
- Revenue
- GRFS $8,821,017,248.00
- AXSM $561,263,000.00
- Revenue This Year
- GRFS $5.31
- AXSM $63.66
- Revenue Next Year
- GRFS $6.02
- AXSM $54.46
- P/E Ratio
- GRFS $16.23
- AXSM N/A
- Revenue Growth
- GRFS 7.31
- AXSM 65.83
- 52 Week Low
- GRFS $6.19
- AXSM $75.56
- 52 Week High
- GRFS $11.14
- AXSM $151.33
- Technical
- Relative Strength Index (RSI)
- GRFS 33.65
- AXSM 72.85
- Support Level
- GRFS $8.33
- AXSM $142.51
- Resistance Level
- GRFS $8.64
- AXSM $149.46
- Average True Range (ATR)
- GRFS 0.21
- AXSM 5.27
- MACD
- GRFS -0.00
- AXSM 0.74
- Stochastic Oscillator
- GRFS 26.21
- AXSM 98.01
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.